A large pharma company wanted to buy Ajax Therapeutics when it was raising a $40 million Series B in 2021. But the startup thought it could do better on its own.
“We thought that the compound at the time, which was part of the abstract in our 2022 ASH presentation, was a progenitor of what we’ve developed today. So we’ve actually made it better,” CEO Martin Vogelbaum told Endpoints News. “And we felt we were the team that could make it better and get to the best compound that we could take into the clinic.”
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.